Alnylam Pharmaceuticals
ALNY
224.41
+0.47
+0.21%
Alnylam Pharmaceuticals
US · ALNY
#627 by market cap
Listed 1970
224.41
+0.47
+0.21%
Live - 5344 symbols - heartbeat 220s ago
· 2026-10-08 06:56
Pre-market
221.00
-1.52%
After-hours
224.41
0.00%
Overnight
224.32
-0.04%
- Market cap
- 30.03B
- P/E (TTM)i
- 39.10
- P/Bi
- 22.17
- EPSi
- 2.33
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on ALNY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.13, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +65.19% YoY
Margins
- Gross margin
- 81.64%
- Operating margin
- 13.51%
- Net margin
- 8.45%
Key ratios & quality
- Enterprise valuei
- 28.17B
- Altman Z-Scorei
- 4.13
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 74.91M | 219.75M | 492.85M | 844.29M | 1.04B | 1.83B | 2.25B | 3.71B |
| Gross profit | 73.11M | 194.69M | 414.80M | 704.14M | 868.60M | 1.52B | 1.92B | 3.03B |
| Selling & admin expenses | 382.36M | 479.01M | 588.42M | 620.64M | 770.66M | 795.65M | 975.53M | 1.21B |
| Research & development | 505.42M | 655.11M | 654.82M | 792.16M | 883.02M | 1.00B | 1.13B | 1.32B |
| Operating profit | -814.67M | -939.43M | -828.44M | -708.65M | -785.07M | -282.18M | -176.89M | 501.58M |
| Pretax profit | -760.67M | -885.25M | -855.60M | -852.14M | -1.13B | -433.52M | -377.38M | 323.15M |
| Tax | 823.00K | 863.00K | 2.68M | 680.00K | 4.16M | 6.73M | -99.22M | 9.41M |
| Net profit | -761.50M | -886.12M | -858.28M | -852.82M | -1.13B | -440.24M | -278.16M | 313.75M |
| Basic EPS | -8 | -8 | -7 | -7 | -9 | -4 | -2 | 2 |
| Diluted EPS | -7.57 | -8.11 | -7.46 | -7.20 | -9.30 | -3.52 | -2.18 | 2.33 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 594.19M | 773.69M | 1.25B | 1.10B | 1.17B | 1.29B |
| Gross profit | 523.15M | 630.74M | 1.05B | 829.31M | 956.05M | 992.50M |
| Selling & admin expenses | 239.95M | 323.31M | 322.08M | 325.37M | 322.55M | 347.92M |
| Research & development | 265.12M | 323.62M | 358.81M | 372.22M | 364.87M | 413.13M |
| Operating profit | 18.08M | -16.20M | 367.98M | 131.72M | 268.64M | 231.44M |
| Pretax profit | -2.37M | -41.31M | 238.97M | 161.14M | 221.65M | 177.81M |
| Tax | 15.88M | 30.92M | -12.12M | -25.28M | 15.66M | 13.31M |
| Net profit | -18.25M | -72.23M | 251.08M | 186.42M | 205.99M | 164.49M |
| Basic EPS | 0 | -1 | 2 | 1 | 2 | 1 |
| Diluted EPS | -0.14 | -0.55 | 1.84 | 0.82 | 1.51 | 1.21 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.20B | 1.72B | 2.61B | 2.81B | 2.69B | 2.98B | 3.30B | 4.05B |
| Cash & ST investments | 1.08B | 1.54B | 1.87B | 2.44B | 2.19B | 2.44B | 2.69B | 2.91B |
| Inventory | 24.07M | 56.35M | 75.20M | 86.36M | 128.96M | 89.15M | 78.51M | 82.72M |
| Total assets | 1.57B | 2.40B | 3.41B | 3.64B | 3.55B | 3.83B | 4.24B | 4.97B |
| Total current liabilities | 179.49M | 352.59M | 585.27M | 695.71M | 767.92M | 967.79M | 1.19B | 1.47B |
| Short-term debt | -- | 27.69M | 36.87M | 40.55M | 41.97M | 41.51M | 41.89M | 45.52M |
| Long-term debt | 30.00M | -- | 191.28M | 675.70M | 1.02B | 1.02B | 1.02B | 1.01B |
| Total liabilities | 272,837,000.00 | 956,442,000.00 | 2,390,814,000.00 | 3,055,101,000.00 | 3,704,582,000.00 | 4,050,524,000.00 | 4,172,895,000.00 | 4,177,155,000.00 |
| Total equity | 1.30B | 1.44B | 1.02B | 588.20M | -158.22M | -220.64M | 67.09M | 789.18M |
| Retained earnings | -2.84B | -3.73B | -4.59B | -5.44B | -6.57B | -7.01B | -7.29B | -6.70B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.27B | 3.64B | 3.95B | 4.05B | 4.22B | 4.62B |
| Cash & ST investments | 2.63B | 2.86B | 2.72B | 2.91B | 3.01B | 3.31B |
| Inventory | 65.58M | 71.69M | 75.38M | 82.72M | 84.03M | 97.11M |
| Total assets | 4.21B | 4.57B | 4.85B | 4.97B | 5.13B | 5.56B |
| Total current liabilities | 1.08B | 1.30B | 1.56B | 1.47B | 1.35B | 1.51B |
| Short-term debt | 46.01M | 46.10M | 44.76M | 45.52M | 45.66M | 45.93M |
| Long-term debt | 1.03B | 1.03B | 1.04B | 1.01B | 1.01B | 1.01B |
| Total liabilities | 4,098,376,000.00 | 4,315,428,000.00 | 4,617,768,000.00 | 4,177,155,000.00 | 4,054,167,000.00 | 4,204,651,000.00 |
| Total equity | 115.44M | 250.59M | 233.89M | 789.18M | 1.08B | 1.35B |
| Retained earnings | -7.35B | -7.41B | -7.16B | -6.70B | -6.50B | -6.33B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -562.62M | -278.43M | -614.96M | -641.69M | -541.27M | 104.16M | -8.31M | 524.08M |
| Depreciation & amortization | 15.25M | 54.37M | 74.44M | 89.69M | 44.47M | 54.05M | 56.67M | 55.66M |
| Free cash flow | -689.50M | -418.58M | -685.32M | -718.07M | -613.33M | 41.95M | -42.59M | 465.38M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 781.90M | 99.50M | -- | -- | -- | -- | -- |
| Ending cash balance | 422.63M | 549.63M | 499.05M | 822.15M | 868.56M | 814.88M | 968.65M | 1.66B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -120.31M | 129.81M | 351.03M | 163.56M | 70.50M | 326.72M |
| Depreciation & amortization | 14.41M | 13.94M | 13.80M | 13.51M | 13.55M | 13.90M |
| Free cash flow | -129.28M | 115.51M | 338.89M | 140.26M | 48.67M | 292.04M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 1.02B | 1.12B | 1.49B | 1.66B | 1.71B | 1.71B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -49.63 | -64.66 | -69.92 | -106.31 | -526.14 | -- | -- | 73.28 |
| ROA %i | -42.67 | -44.64 | -29.58 | -24.19 | -31.47 | -11.94 | -6.89 | 6.82 |
| ROIC %i | -50.05 | -58.70 | -49.10 | -48.00 | -75.25 | -- | -- | 26.28 |
| 5-year avg ROE %i | -41.96 | -42.95 | -51.66 | -65.41 | -163.33 | -- | -- | -- |
| EBIT margin %i | -1,087.56 | -427.50 | -156.46 | -83.99 | -93.60 | -17.08 | -10.48 | 15.50 |
| FCF / sales %i | -- | -- | -- | -- | -- | 2.29 | -- | 12.53 |
| Current ratioi | 6.69 | 4.87 | 4.47 | 4.04 | 3.51 | 3.08 | 2.78 | 2.76 |
| Quick ratioi | 6.14 | 4.48 | 4.23 | 3.79 | 3.16 | 2.86 | 2.61 | 2.51 |
| Debt / assetsi | 1.91 | 12.69 | 15.30 | 27.38 | 37.23 | 34.08 | 30.57 | 25.74 |
| LT debt / equityi | 2.30 | 19.19 | 47.66 | 162.71 | -- | -- | 1,869.43 | 156.22 |
| Interest coveragei | -- | -- | -9.13 | -4.96 | -6.23 | -2.58 | -1.66 | 2.28 |
| Revenue CAGR (3Y) %i | 22.15 | 67.03 | 76.32 | 124.21 | 67.75 | 54.80 | 38.61 | 52.98 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -257.82 | 32.73 | 73.28 | 90.36 | 96.55 |
| ROA %i | -6.71 | -7.44 | 0.96 | 6.82 | 11.52 | 15.30 |
| ROIC %i | -- | -20.46 | 5.43 | 26.28 | 36.63 | 42.18 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -8.95 | -9.23 | 4.06 | 15.50 | 18.91 | 21.87 |
| FCF / sales %i | -- | -- | 6.90 | 12.53 | 15.01 | 17.07 |
| Current ratioi | 3.04 | 2.80 | 2.54 | 2.76 | 3.13 | 3.05 |
| Quick ratioi | 2.84 | 2.63 | 2.37 | 2.51 | 2.88 | 2.79 |
| Debt / assetsi | 30.89 | 28.41 | 26.97 | 25.74 | 24.82 | 22.80 |
| LT debt / equityi | 1,087.74 | 499.21 | 540.29 | 156.22 | 114.14 | 90.20 |
| Interest coveragei | -1.45 | -1.49 | 0.80 | 2.28 | 3.08 | 3.70 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- AMVUTTRA is the largest reported line at 78.37% of revenue, across 6 reported segments.
- The next-largest line, GIVLAARI, is a distant second at 6.95% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
AMVUTTRA78.37%
GIVLAARI6.95%
Royalty revenue5.55%
OXLUMO4.04%
Net revenues from collaborations3.65%
ONPATTRO1.43%
Quote time 2026-10-08 06:56:41 · For reference only, not investment advice and not tailored to your situation.